Legend Biotech Corporation (DE:9LB)
NASDAQ:9LB
9LB Stock Chart & Stats
€18.00
-€0.40(-1.24%)
At close: 4:00 PM EST
€18.00
-€0.40(-1.24%)
Day’s Range― - ―
52-Week Range€13.80 - €38.00
Previous CloseN/A
Volume0.00
Average Volume (3M)36.00
Market Cap
€5.38B
Enterprise Value€5.94B
Total Cash (Recent Filing)€834.63M
Total Debt (Recent Filing)€389.31M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 18, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding185,739,790
10 Day Avg. Volume83
30 Day Avg. Volume36
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)4.00
Price to Sales (P/S)3.89
P/FCF Ratio-23.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€49.62Price Target Upside175.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.08
Revenue Forecast (FY)€1.25B
Bulls Say, Bears Say
Bulls Say
Commercial Traction (CARVYKTI)Sustained high single-product sales growth reflects durable market adoption in multiple myeloma, earlier-line penetration, and expanding treatment sites. This scale underpins margin recovery, funds reinvestment, and materially strengthens the company's path to company-wide adjusted profitability over the next 2–3 years.
Manufacturing & OperationsReliable, high-yield manufacturing with fast turnaround is a durable competitive advantage for autologous CAR‑T supply. It reduces treatment bottlenecks, supports broader community adoption, lowers per-patient logistics risk, and enables predictable scale-up that should sustainably improve gross margins as volume grows.
Balance Sheet LiquidityA strong cash position and minimal long-term debt provide multi-quarter funding flexibility to invest in manufacturing, commercial expansion, and early‑stage programs without immediate financing. This reduces near-term dilution risk and supports execution toward adjusted profitability and strategic IND filings.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow is a structural vulnerability for a commercial-stage biotech. If improvements toward positive cash generation slip, the company may need to access capital, which can dilute equity, constrain strategic optionality, or delay investments in manufacturing and pipeline expansion over the medium term.
Pivotal Trial Timing RiskLabel expansions and sizable revenue upside depend on event-driven pivotal readouts. Uncertain timing creates a durable execution risk: delayed or disappointing readouts would slow earlier-line adoption, compress the revenue growth trajectory, and postpone milestone or royalty flows that materially affect long-term commercial scale.
Collaboration Accounting & Revenue ClarityMaterial gaps between partner trade sales and company‑recognized revenue reflect collaboration accounting complexity. This obscures the direct economics and timing of cash flows, complicates forecasting and margin visibility over time, and can mask the true conversion of commercial demand into company revenue and profits.
Legend Biotech News
9LB FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was €13.80 and its highest was €38.00 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is €5.38B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Aug 18, 2026 which is in 60 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on May 12, 2026. The company reported -€0.13 earnings per share for the quarter, missing the consensus estimate of €0.01 by -€0.14.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is 0.07.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 185,739,790 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -€0.13 in its last earnings report, missing expectations of €0.01. Following the earnings report the stock price went up 10.185%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in DE:9LB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Legend Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€49.62 (175.66% Upside)
€49.62 (175.66% Upside)
Blogger Sentiment
Bullish
DE:9LB Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €75.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.40%
12-Months-Change
Fundamentals
Return on Equity
-24.91%
Trailing 12-Months
Asset Growth
-1.17%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation is a clinical-stage biopharmaceutical firm, operating through its various subsidiaries, dedicated to the discovery and advancement of innovative cell therapies. These treatments primarily target oncological conditions but also address other diseases across the United States, China, and international markets. The company's most advanced investigational therapy is LCAR-B38M, a chimeric antigen receptor (CAR) product specifically developed for treating multiple myeloma (MM). This lead candidate is currently undergoing comparative evaluation against standard triplet therapies in patients suffering from revlimid-refractory multiple myeloma. Additionally, Legend Biotech possesses a pipeline of early-stage, autologous product candidates, which are presently in Phase I clinical trials for addressing gastric cancer and T-cell lymphoma. The company is also actively developing CAR-T cell therapies designed to target CD20, CD22, and CD19 for the treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further expanding its therapeutic scope, the firm has product candidates in both early preclinical and clinical development phases aimed at solid tumors and infectious diseases. A significant collaboration exists with Janssen Biotech, Inc., for the joint development and commercialization of ciltacabtagene autoleucel. Founded in 2014, Legend Biotech Corporation is based in Somerset, New Jersey, and functions as a subsidiary of Genscript Biotech Corporation.
9LB Company Deck
9LB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and operational performance—notably robust CARVYKTI sales growth (52% YoY), improved manufacturing metrics (99% success, 29-day turnaround), deeper earlier-line penetration (41% vs 29% YoY), a solid cash position (~$835M), and a clear path to adjusted profitability in 2026. These positives are tempered by a near-term gross margin hit (41% vs 57% prior quarter) from one-time manufacturing ramp costs, an adjusted net loss still present in Q1, event-driven uncertainty around pivotal readouts (CARTITUDE-5/6), and early-stage clinical risk for the In Vivo programs where safety/efficacy data are not yet disclosed. On balance, the highlights (strong growth, manufacturing execution, expanding pipeline, balance sheet strength, path to profitability) outweigh the lowlights, supporting a constructive view of the company's near- to mid-term outlook.View all DE:9LB earnings summaries9LB Stock 12 Month Forecast
Average Price Target
€49.62
▲(175.66% Upside)
Technical Analysis
Cytokinetics
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Options Prices
Currently, No data available
---